Study of NTB003 for Thyroid Eye Disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new drug called NTB003 for people with moderate-to-severe thyroid eye disease (TED). It aims to see if the drug can improve symptoms like eye bulging and double vision, and it may be an option for those whose disease is active or has been ongoing for a while.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and weigh between 88 and 220 pounds.
- You have been diagnosed with thyroid eye disease (TED) that is either active (symptoms started within the last year) or chronic (symptoms started more than a year ago).
- Your TED is moderate-to-severe, meaning your eye bulging is at least 3 mm above normal and you have other symptoms like eyelid pulling back, swollen tissues, or double vision.
- You do not need immediate eye surgery or radiation therapy for TED, and you agree not to have any during the study.
- Your thyroid condition is under control (free T3 and free T4 levels not more than 50% above or below normal).
- You have not used certain treatments like steroids, immune-suppressing drugs, or specific supplements for TED in the past few weeks or months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
This trial tests a new medication, KHN939, for people with moderate-to-severe active thyroid eye disease. It aims to reduce eye bulging and other symptoms.
This trial tests a new drug, KHN939, for people with moderate-to-severe thyroid eye disease that is no longer active. It aims to see if the drug can improve symptoms like bulging eyes, eyelid retraction, or double vision.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.